Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Enveric Biosciences Inc (ENVB) vs Innodata Inc (INOD) Price & Performance

Enveric Biosciences IncTrade
Innodata IncTrade

Price performance (Past 24H)

Key statistics

Enveric Biosciences Inc vs Innodata Inc — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while Innodata Inc trades at $62.8 (market cap $2.03B). The key difference: Innodata Inc is far larger — about 327.4× Enveric Biosciences Inc's market cap, and Innodata Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.

ENVBINOD
Market Cap
$6.20M$2.03B
Sector
HealthTechnology
52-Week High
$17.40$121.50
52-Week Low
$1.27$34.45
Enterprise Value
$1.30M$1.79B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Enveric Biosciences Inc

ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.

Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.

Innodata Inc

INOD trades at $62.33, down 4.81% over 24 hours, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.41 versus $0.21 expected, driven by 58% revenue growth and AI demand expansion. Valuation ratios remain elevated, with a P/E of 48.24 and P/S of 6.79, reflecting high growth expectations. Recent news highlights AI-driven growth and leadership transition plans.

Outlook is positive due to robust AI momentum and earnings beats, but risks include premium valuation and customer concentration. Analyst consensus is bullish with a $130 price target, suggesting significant upside from current levels. Investors should weigh growth potential against execution risks in a competitive AI services market.

Returns comparison

Trailing returns across standard periods

About Enveric Biosciences Inc

Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.

Read more on ENVB

About Innodata Inc

Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.

Read more on INOD